New Reference: Trastuzumab Emtansine in HER2-Positive Breast Cancer with Residual Disease
Study
Phase 3, multicenter, randomized, controlled trial (KATHERINE)
|
HER2-positive early breast cancer with residual invasive cancer after neoadjuvant therapy
|
T-DM1 vs. trastuzumab (14 cycles every 3 weeks)
|
Efficacy
7-yr IDFS: 80.8% vs. 67.1% (T-DM1 vs. trastuzumab) (HR: 0.54 [0.44-0.66])
|
Distant recurrence: 14.7% vs. 21.5%
|
CNS recurrence (first invasive-disease event): 7.0% vs. 5.1%
|
CNS recurrence (subsequent): 0.5% vs. 2.6%
|
7-yr OS: 89.1% vs. 84.4% (HR: 0.66 [0.51-0.87], P=0.003)
|
Safety
Grade ≥3 AEs: 26.1% vs. 15.7% (T-DM1 vs. trastuzumab)
|
Serious AEs: 12.7% vs. 8.1%
|
Cardiac and other toxic effects: Rare in both groups
|
Geyer CE,Untch M,Huang CS Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
Reviewed by Ulas D. Bayraktar, MD on Jan 24, 2025
